公开(公告)号：EP2961727B1

公开(公告)日：2016-12-28

申请号：EP14730991.8

申请日：2014-02-27

申请人： Pronova BioPharma Norge AS

发明人： SKJÆRET, Tore ,  HOVLAND, Ragnar

IPC分类号： C07C51/367 ,  C07C51/47 ,  C07C29/147 ,  C07C59/60 ,  C07C33/02

CPC分类号： C07C51/367 ,  C07C29/147 ,  C07C51/42 ,  C07C51/47 ,  C07C59/60 ,  C07C33/02

公开(公告)号：EP2635270A1

公开(公告)日：2013-09-11

申请号：EP11837647.4

申请日：2011-11-03

申请人： Pronova BioPharma Norge AS

发明人： HOVLAND, Ragnar ,  SKJÆRET, Tore ,  FRASER, David A.

IPC分类号： A61K31/19 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P9/10 ,  C07C57/03

CPC分类号： C07C69/734 ,  A61K31/19 ,  A61K31/355 ,  C07C59/60 ,  C07D263/26 ,  A61K2300/00

摘要： Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I): (I) or a pharmaceutically acceptable salt, or ester thereof, wherein R
1 and R
2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C
1 -C
6 alkyl groups, with the proviso that R
1 and R
2 are not both hydrogen or a pharmaceutically acceptable salt or ester thereof. Such diseases or conditions may relate to coronary heart disease (CHD), for example atherosclerosis; metabolic syndrome/insulin resistance; and/or a dyslipidemic condition such as hypertriglyceridemia (HTG), elevated LDL- cholesterol, elevated total-cholesterol, elevated Apo B and low HDL-cholesterol. The present disclosure further provides for a method of reducing atherosclerosis development. Pharmaceutical compositions comprising a compound of Formula (I) are also disclosed.

公开(公告)号：EP2526084A1

公开(公告)日：2012-11-28

申请号：EP11734428.3

申请日：2011-01-20

申请人： Pronova BioPharma Norge AS

发明人： HOVLAND, Ragnar ,  SKJÆRET, Tore ,  ROSMAN, Jenny

IPC分类号： C07C233/49 ,  A61K31/166 ,  A61K31/167 ,  A61K31/194 ,  A61P3/00 ,  A61P29/00 ,  C07C65/19 ,  C07C233/55 ,  C07C233/64 ,  C07C321/20

CPC分类号： C07C323/60 ,  C07C59/60 ,  C07C69/734 ,  C07C235/08 ,  C07C235/10 ,  C07C235/12 ,  C07C235/16 ,  C07C235/60 ,  C07C237/22 ,  C07C265/04 ,  C07C271/16 ,  C07C271/20 ,  C07C271/28 ,  C07C275/42 ,  C07C323/52

摘要： Fatty acid conjugates of salicylate derivatives and compositions thereof are disclosed. Further disclosed are methods for treating and/or preventing an inflammatory disease including inflammation and/or inflammatory bowel disease (IBD), dyslipidemia including mixed dyslipidemia and/or hypertriglyceridemia, elevated blood lipids including, e.g., triglycerides and/or cholesterol, metabolic syndrome, peripheral insulin resistance, diabetes, atherosclerosis; a method for lowering non-HDL cholesterol; and a method for raising HDL-cholesterol comprising the administration of an effective amount of at least one compound according to the present disclosure.

公开(公告)号：EP2635270B1

公开(公告)日：2016-12-21

申请号：EP11837647.4

申请日：2011-11-03

申请人： Pronova BioPharma Norge AS

发明人： HOVLAND, Ragnar ,  SKJÆRET, Tore ,  FRASER, David A.

IPC分类号： A61K31/19 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P9/10 ,  C07C57/03

CPC分类号： C07C69/734 ,  A61K31/19 ,  A61K31/355 ,  C07C59/60 ,  C07D263/26 ,  A61K2300/00

公开(公告)号：EP2961727A2

公开(公告)日：2016-01-06

申请号：EP14730991.8

申请日：2014-02-27

申请人： Pronova BioPharma Norge AS

发明人： SKJÆRET, Tore ,  HOVLAND, Ragnar

IPC分类号： C07C51/367 ,  C07C51/47 ,  C07C29/147 ,  C07C59/60 ,  C07C33/02

CPC分类号： C07C51/367 ,  C07C29/147 ,  C07C51/42 ,  C07C51/47 ,  C07C59/60 ,  C07C33/02

摘要： Methods for the efficient synthesis of fatty acid derivatives and their intermediates are provided.

摘要翻译： 提供了有效合成脂肪酸衍生物及其中间体的方法。

公开(公告)号：EP2427415A1

公开(公告)日：2012-03-14

申请号：EP10772077.3

申请日：2010-05-07

申请人： Pronova BioPharma Norge AS

发明人： HOVLAND, Ragnar ,  HOLMEIDE, Anne Kristin ,  SKJÆRET, Tore ,  BRÆNDVANG, Morten

IPC分类号： C07C57/03 ,  A61K31/19 ,  A61K31/22 ,  A61P19/02 ,  A61P29/00 ,  A61P3/10 ,  A61P9/10 ,  C07C69/587

CPC分类号： C07D263/26 ,  A61K31/19 ,  A61K31/22 ,  A61K31/421 ,  A61K45/06 ,  C07B2200/07 ,  C07C51/367 ,  C07C59/60 ,  C07C67/31 ,  C07C69/675 ,  C07C69/68 ,  C07C69/708

摘要： The present disclosure relates to lipid compounds of the general formula (I): R1-O-C(R2)(R3) -X (I) wherein R
1 is a C
10 -C
22 alkyl group, a C
10 -C
22 alkenyl group having 1-6 double bonds, or a C
10 -C
22 alkynyl group having 1-6 triple bonds; R
2 and R
3 are the same or different and may be chosen from different substituents; and X is a carboxylic acid or a derivative thereof, such as a carboxylic ester, a carboxylic anhydride, a phospholipid, triglyceride, or a carboxamide; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic, and inflammatory disease area.